Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

HMS faculty, help us improve the algorithms in Profiles by uploading your CV!

Elisabetta Patorno, Dr.P.H., M.D.

Co-Author

This page shows the publications co-authored by Elisabetta Patorno and Seoyoung Kim.
Connection Strength

8.735
  1. Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease. Ann Intern Med. 2022 01; 175(1):W4-W5.
    View in: PubMed
    Score: 0.951
  2. Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease. Ann Intern Med. 2022 01; 175(1):W4.
    View in: PubMed
    Score: 0.951
  3. Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease. Ann Intern Med. 2021 11; 174(11):1528-1541.
    View in: PubMed
    Score: 0.934
  4. Comparative Effectiveness and Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults. Diabetes Care. 2021 03; 44(3):826-835.
    View in: PubMed
    Score: 0.891
  5. Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study. BMJ. 2018 02 06; 360:k119.
    View in: PubMed
    Score: 0.725
  6. Comparative cardiovascular safety of glucagon-like peptide-1 receptor agonists versus other antidiabetic drugs in routine care: a cohort study. Diabetes Obes Metab. 2016 08; 18(8):755-65.
    View in: PubMed
    Score: 0.642
  7. Cardiovascular and Mortality Risk with Intravitreal Vascular Endothelial Growth Factor Inhibitors in Patients with Diabetic Retinopathy. Ophthalmol Retina. 2022 Jun 28.
    View in: PubMed
    Score: 0.246
  8. Three Sides to the Story: Adherence Trajectories During the First Year of SGLT2 Inhibitor Therapy Among Medicare Beneficiaries. Diabetes Care. 2022 03 01; 45(3):604-613.
    View in: PubMed
    Score: 0.240
  9. Accuracy of identifying diagnosis of moderate to severe chronic kidney disease in administrative claims data. Pharmacoepidemiol Drug Saf. 2022 04; 31(4):467-475.
    View in: PubMed
    Score: 0.237
  10. Misclassification of Obesity in Claims Data. Clin Transl Gastroenterol. 2021 11 18; 12(11):e00423.
    View in: PubMed
    Score: 0.236
  11. SGLT2 Inhibitors and the Risk of Acute Kidney Injury in Older Adults With Type 2 Diabetes. Am J Kidney Dis. 2022 06; 79(6):858-867.e1.
    View in: PubMed
    Score: 0.235
  12. Association of Sodium-Glucose Cotransporter-2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes. JAMA Netw Open. 2021 10 01; 4(10):e2130762.
    View in: PubMed
    Score: 0.234
  13. Validation of obesity-related diagnosis codes in claims data. Diabetes Obes Metab. 2021 12; 23(12):2623-2631.
    View in: PubMed
    Score: 0.232
  14. Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy. Circulation. 2021 02 23; 143(8):770-779.
    View in: PubMed
    Score: 0.221
  15. Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study. BMJ. 2020 08 25; 370:m2812.
    View in: PubMed
    Score: 0.216
  16. Assessing the Risk for Gout With Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes: A Population-Based Cohort Study. Ann Intern Med. 2020 02 04; 172(3):186-194.
    View in: PubMed
    Score: 0.207
  17. Fracture Risk After Initiation of Use of Canagliflozin. Ann Intern Med. 2019 07 02; 171(1):80.
    View in: PubMed
    Score: 0.200
  18. Fracture Risk After Initiation of Use of Canagliflozin: A Cohort Study. Ann Intern Med. 2019 02 05; 170(3):155-163.
    View in: PubMed
    Score: 0.193
  19. Comparative Cardiovascular Risk of Abatacept and Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis With and Without Diabetes Mellitus: A Multidatabase Cohort Study. J Am Heart Assoc. 2018 01 24; 7(3).
    View in: PubMed
    Score: 0.181
  20. Risk of serious infections associated with use of immunosuppressive agents in pregnant women with autoimmune inflammatory conditions: cohort study. BMJ. 2017 Mar 06; 356:j895.
    View in: PubMed
    Score: 0.170
  21. Brief Report: Patterns and Secular Trends in Use of Immunomodulatory Agents During Pregnancy in Women With Rheumatic Conditions. Arthritis Rheumatol. 2016 05; 68(5):1183-9.
    View in: PubMed
    Score: 0.160
  22. Patients' perception about risks and benefits of antithrombotic treatment for the prevention of venous thromboembolism (VTE) after orthopedic surgery: a qualitative study. BMC Musculoskelet Disord. 2015 Oct 26; 16:319.
    View in: PubMed
    Score: 0.155
  23. Risk of Hospitalization for Heart Failure in Patients With Hyperkalemia Treated With Sodium Zirconium Cyclosilicate Versus Patiromer. J Card Fail. 2022 Apr 22.
    View in: PubMed
    Score: 0.061
  24. Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis. Cardiovasc Diabetol. 2022 03 23; 21(1):47.
    View in: PubMed
    Score: 0.060
  25. Prescribing Trends of Antidiabetes Medications in Patients With Type 2 Diabetes and Diabetic Kidney Disease, a Cohort Study. Diabetes Care. 2021 Aug 03.
    View in: PubMed
    Score: 0.058
  26. A tool for empirical equipoise assessment in multigroup comparative effectiveness research. Pharmacoepidemiol Drug Saf. 2019 07; 28(7):934-941.
    View in: PubMed
    Score: 0.050
  27. Multinomial Extension of Propensity Score Trimming Methods: A Simulation Study. Am J Epidemiol. 2019 03 01; 188(3):609-616.
    View in: PubMed
    Score: 0.049
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.